Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study

Abstract

RATIONALE & OBJECTIVE: Gabapentinoids are opioid substitutes whose elimination by the kidneys is reduced as kidney function declines. To inform their safe prescribing in older adults with chronic kidney disease (CKD), we examined the 30-day risk of serious adverse events according to the prescribed starting dose. STUDY DESIGN: Population-based cohort study.

Authors

Muanda FT; Weir MA; Ahmadi F; Sontrop JM; Cowan A; Fleet JL; Blake PG; Garg AX

Journal

American Journal of Kidney Diseases, Vol. 80, No. 1, pp. 98–107.e1

Publisher

Elsevier

Publication Date

July 2022

DOI

10.1053/j.ajkd.2021.11.007

ISSN

0272-6386

Associated Experts

Amit Garg

Assistant Professor (Part-Time), Faculty of Health Sciences

Visit profile

Labels